GlassScriptPhysician profile
Shail Maingi
NPI 1114183795
$5,274.95
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,882 · 2020: $315 · 2021: $11.92 · 2022: $121 · 2023: $103 · 2024: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $420.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,863.75 | 2019-2020 | |
| Daiichi Sankyo INC. | $656.40 | 2020-2024 | Enhertu |
| Genentech USA, INC. | $183.63 | 2024 | |
| Epizyme, INC. | $120.83 | 2022 | |
| Seagen INC. | $118.23 | 2019-2023 | Padcev |
| Genmab U.S., INC. | $107.23 | 2024 | Epkinly |
| Merck Sharp & Dohme LLC | $96.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $47.97 | 2020 | |
| Abbvie INC. | $27.16 | 2024 | |
| Emd Serono, INC. | $15.24 | 2019 | |
| Celgene Corporation | $14.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.22 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shail Maingi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.